Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired...(perforation -- In patients with sever...),Health

-- In patients with severe hepatic impairment (Child Pugh C), the initial

dose of TYGACIL should be 100 mg followed by 25 mg every 12 hours.

Patients should be treated with caution and monitored for treatment

response

-- The following drugs should not be administered simultaneously through

the same Y-site as TYGACIL: amphotericin B and diazepam

For a copy of TYGACIL Prescribing Information, please visit http://www.Wyeth.com.

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In particular, there can be no assurance that our pending supplemental new drug application for TYGACIL for the CAP indication will be approved or that the product will ever be successfully commercialized for CAP or other indications. Other risks and uncertainties that could cause actual results to differ materially from those expressed or implied by forward-looking statements include, without limitation, the inherent uncertainty of the timi
'/>"/>